Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2Lymphoid 1

Conditions

Gastro-enteropancreatic neuroendocrine tumor 2Prolactin-Producing Pituitary Tumor 1Lymphoma, Follicular 1

Interventions

lutetium Lu 177 dotatate 6Octreotide 3pasireotide 2lanreotide 2gallium Ga 68 dotatate 2copper dotatate CU-64 2amino-acid, glucose, and electrolyte solution 2Magnetic Resonance Spectroscopy 2Lutetium-177 2Lutetium 2Ga(III)-DOTATOC 2Everolimus 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2zimberelimab 1irinotecan sucrosofate 1abemaciclib 1X-Rays 1Temozolomide 1Sunitinib 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Radiosurgery 1PM 01183 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Ipilimumab 1Folfox protocol 1Fluorouracil 1E-7386 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × pasireotide × 1 year × Clear all
NCT06784752 2026-04-30

NETTER-3

Novartis

Phase 3 Recruiting
240 enrolled
EndocrineGastrointestinalLymphoidNET

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Follicular

NCT03972488 2026-01-21

NETTER-2

Advanced Accelerator Applications

Phase 3 Active not recruiting
226 enrolled 14 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡